A new antibiotic combo for mycobacterium abscessus lung infection
Treatments studied
Part of Infections clinical trials.
This trial tests a new combination of antibiotics (Arm D) against the standard treatment for people with a difficult-to-treat lung infection called Mycobacterium abscessus. It is for adults and teens aged 12 and older, including those with cystic fibrosis.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 12 years old or older.
- You have a lung infection caused by Mycobacterium abscessus.
- You do not have severe kidney problems (for those under 18).
- You are not allergic to any of the medicines in the trial: sulbactam/durlobactam, ceftriaxone, amoxicillin, macrolide antibiotics (like azithromycin), or clofazimine.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a new antibiotic, Contezolid, can quickly reduce the amount of Mycobacterium abscessus in your lungs. It may be a treatment option if you have had a positive sputum test in the past 6 months.
This study tests an investigational medication called epetraborole for people with a chronic lung infection caused by Mycobacterium abscessus bacteria. You may be able to join if your infection is stable enough to delay standard treatment and you have symptoms like cough, fatigue, or weight loss.
This study tests if adding traditional Chinese medicine to standard treatment helps people with a lung infection called Mycobacterium abscessus. It may improve recovery and reduce side effects.
This trial tests whether omadacycline (an antibiotic) can safely and effectively treat a rare lung infection caused by Mycobacterium abscessus bacteria. If you have this infection, this study may help doctors understand if this antibiotic works better than current treatments.
This is a special program for one patient with a lung infection from Mycobacterium abscessus. The trial uses a treatment with bacteriophages, which are viruses that attack specific bacteria.
This study looks for the best way to treat Mycobacterium abscessus (MABS), a difficult lung infection. You may join a treatment group, or first join an observation group and possibly move into treatment later if you meet the criteria.
Hear when a new Mycobacterium Abscessus Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.